Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma

NCT04775680 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
25
Enrollment
INDUSTRY
Sponsor class

Stopped The safety of ADG106 combined with triprilimab has been fully understood.The overall clinical benefit of enrolled subjects was limited and further development of ADG106 was reconsidered.

Conditions

Interventions

Sponsor

Adagene (Suzhou) Limited